Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897466202> ?p ?o ?g. }
- W2897466202 endingPage "862" @default.
- W2897466202 startingPage "855" @default.
- W2897466202 abstract "Background Long-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the recommended initial maintenance treatment for chronic obstructive pulmonary disease (COPD), with almost all LABAs dispensed in fixed combination with inhaled corticosteroids (LABA-ICS). We compared the effectiveness and safety of LABA-ICS versus LAMA treatment initiation as a function of blood eosinophilia, a potential biomarker of ICS effectiveness, in a real-world setting. Methods In this population-based cohort study, we identified a cohort of patients with COPD initiating treatment with a LAMA or LABA-ICS during 2002–15, age 55 years or older, from the UK's Clinical Practice Research Datalink. We excluded patients who initiated treatment with both bronchodilators on the same date. All patients required at least 1 year of medical history and a measure of blood eosinophil concentration before cohort entry, defined by the date of the first cohort-defining bronchodilator prescription. Patients initiating a LAMA were matched on high-dimensional propensity scores with patients initiating a LABA-ICS. They were followed up for 1 year for the occurrence of a moderate or severe COPD exacerbation and for severe pneumonia. Sensitivity analyses included, among others, repeating the analysis among patients with two blood eosinophil concentration measures and stratification by concurrent asthma and previous exacerbations. Findings The base cohort included 539 643 patients with a prescription for LABAs or LAMAs from Jan 1, 2002, to Dec 31, 2015, of whom 18 500 were initiated on LABA-ICS and 13 870 on LAMAs. Propensity score analysis resulted in 12 366 initiators of LAMAs (mainly tiotropium) matched to 12 366 initiators of LABA-ICS. The hazard ratio (HR) of COPD exacerbation associated with LABA-ICS initiation, relative to LAMA initiation, was 0·95 (95% CI 0·90–1·01). In patients with blood eosinophil concentrations of less than 2% of white blood cell count, the HR was 1·03 (95% CI 0·93–1·13) and for those with eosinophil concentrations of 2–4%, the HR was 1·00 (0·91–1·10). For patients with eosinophil concentrations of more than 4%, the HR was 0·79 (0·70–0·88). The incidence of pneumonia increased with LABA-ICS initiation (HR 1·37 [95% CI 1·17–1·60]) and was similar across all eosinophil concentrations. Sensitivity analyses were consistent with these findings, but the incidence of exacerbation with LABA-ICS among the 2766 (11%) of all 24 732 patients with two or more COPD exacerbations during the baseline year was marginally lower (HR 0·87 [95% CI 0·79–0·97]). Interpretation In this real-world, clinical practice, observational study, initial COPD treatment with LABA-ICS inhalers was only more effective than with LAMAs in patients with high blood eosinophil concentrations (>4%) or counts (>300 cells per μL) and possibly in frequent exacerbators. Because of the increased risk of pneumonia associated with the ICS component, initiation with a LAMA should be preferred in patients with blood eosinophil concentrations of less than 4%. Funding Canadian Institutes of Health Research, Canadian Foundation for Innovation." @default.
- W2897466202 created "2018-10-26" @default.
- W2897466202 creator A5007497866 @default.
- W2897466202 creator A5008217187 @default.
- W2897466202 creator A5017432882 @default.
- W2897466202 date "2018-11-01" @default.
- W2897466202 modified "2023-10-15" @default.
- W2897466202 title "Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study" @default.
- W2897466202 cites W1548901178 @default.
- W2897466202 cites W1963502153 @default.
- W2897466202 cites W1967862917 @default.
- W2897466202 cites W1980668546 @default.
- W2897466202 cites W1983791153 @default.
- W2897466202 cites W1987555297 @default.
- W2897466202 cites W1987881697 @default.
- W2897466202 cites W2079396916 @default.
- W2897466202 cites W2096723137 @default.
- W2897466202 cites W2115260439 @default.
- W2897466202 cites W2119852447 @default.
- W2897466202 cites W2146734665 @default.
- W2897466202 cites W2158978379 @default.
- W2897466202 cites W2159276720 @default.
- W2897466202 cites W2163589808 @default.
- W2897466202 cites W2172005465 @default.
- W2897466202 cites W2172490363 @default.
- W2897466202 cites W2192441381 @default.
- W2897466202 cites W2226119967 @default.
- W2897466202 cites W2228156572 @default.
- W2897466202 cites W2279631877 @default.
- W2897466202 cites W2295597785 @default.
- W2897466202 cites W2312757847 @default.
- W2897466202 cites W2324038222 @default.
- W2897466202 cites W2482855087 @default.
- W2897466202 cites W2510069075 @default.
- W2897466202 cites W2512624858 @default.
- W2897466202 cites W2530594118 @default.
- W2897466202 cites W2591703652 @default.
- W2897466202 cites W2594397173 @default.
- W2897466202 cites W2594716548 @default.
- W2897466202 cites W2610549424 @default.
- W2897466202 cites W2715795126 @default.
- W2897466202 cites W2744121074 @default.
- W2897466202 cites W4210349548 @default.
- W2897466202 cites W4211263216 @default.
- W2897466202 doi "https://doi.org/10.1016/s2213-2600(18)30368-0" @default.
- W2897466202 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30343028" @default.
- W2897466202 hasPublicationYear "2018" @default.
- W2897466202 type Work @default.
- W2897466202 sameAs 2897466202 @default.
- W2897466202 citedByCount "74" @default.
- W2897466202 countsByYear W28974662022018 @default.
- W2897466202 countsByYear W28974662022019 @default.
- W2897466202 countsByYear W28974662022020 @default.
- W2897466202 countsByYear W28974662022021 @default.
- W2897466202 countsByYear W28974662022022 @default.
- W2897466202 countsByYear W28974662022023 @default.
- W2897466202 crossrefType "journal-article" @default.
- W2897466202 hasAuthorship W2897466202A5007497866 @default.
- W2897466202 hasAuthorship W2897466202A5008217187 @default.
- W2897466202 hasAuthorship W2897466202A5017432882 @default.
- W2897466202 hasConcept C126322002 @default.
- W2897466202 hasConcept C201903717 @default.
- W2897466202 hasConcept C2776042228 @default.
- W2897466202 hasConcept C2776780178 @default.
- W2897466202 hasConcept C2777014857 @default.
- W2897466202 hasConcept C2780911369 @default.
- W2897466202 hasConcept C2781018748 @default.
- W2897466202 hasConcept C2908647359 @default.
- W2897466202 hasConcept C71924100 @default.
- W2897466202 hasConcept C72563966 @default.
- W2897466202 hasConcept C99454951 @default.
- W2897466202 hasConceptScore W2897466202C126322002 @default.
- W2897466202 hasConceptScore W2897466202C201903717 @default.
- W2897466202 hasConceptScore W2897466202C2776042228 @default.
- W2897466202 hasConceptScore W2897466202C2776780178 @default.
- W2897466202 hasConceptScore W2897466202C2777014857 @default.
- W2897466202 hasConceptScore W2897466202C2780911369 @default.
- W2897466202 hasConceptScore W2897466202C2781018748 @default.
- W2897466202 hasConceptScore W2897466202C2908647359 @default.
- W2897466202 hasConceptScore W2897466202C71924100 @default.
- W2897466202 hasConceptScore W2897466202C72563966 @default.
- W2897466202 hasConceptScore W2897466202C99454951 @default.
- W2897466202 hasIssue "11" @default.
- W2897466202 hasLocation W28974662021 @default.
- W2897466202 hasLocation W28974662022 @default.
- W2897466202 hasOpenAccess W2897466202 @default.
- W2897466202 hasPrimaryLocation W28974662021 @default.
- W2897466202 hasRelatedWork W2061814643 @default.
- W2897466202 hasRelatedWork W2767263702 @default.
- W2897466202 hasRelatedWork W2773071989 @default.
- W2897466202 hasRelatedWork W2894474424 @default.
- W2897466202 hasRelatedWork W2950569478 @default.
- W2897466202 hasRelatedWork W2951336120 @default.
- W2897466202 hasRelatedWork W3047874532 @default.
- W2897466202 hasRelatedWork W4225112613 @default.
- W2897466202 hasRelatedWork W4230984066 @default.
- W2897466202 hasRelatedWork W4248150072 @default.
- W2897466202 hasVolume "6" @default.